SCHEMBL1134331

SCHEMBL1134331

FC(F)Oc1ccccc1.O=S(=O)(Cl)Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.43
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TEAD4 Q15561 1/20 0.42
ALOX15 P16050 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
DAGLA Q9Y4D2 2/20 0.41
DRD1 P21728 2/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
ATM Q13315 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
LMNA P02545 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL153060 0.86 ALDH1A1 (0.50) ALDH1A1MAPTMEN1KMT2ATEAD4
Formaldehyde SCHEMBL29144546 0.84 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2ATEAD4
Methylamine SCHEMBL28014346 0.79 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2ATEAD4
Methyl Alcohol SCHEMBL28291167 0.79 MAPT (0.46) ALDH1A1MAPTMEN1KMT2ATEAD4
SCHEMBL3038523 0.78 KMT2A (0.49) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL22954612 0.78 HTR6 (0.54) ALDH1A1MAPTMEN1KMT2ATEAD4
SCHEMBL27298212 0.77 LMNA (0.47) MAPTMEN1KMT2ARAB9ADRD1
SCHEMBL2494886 0.77 CES2 (0.44) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL10747381 0.77 DAGLA (0.38) ALDH1A1MAPTMEN1KMT2ATEAD4
SCHEMBL17104921 0.77 ALDH1A1 (0.45) ALDH1A1MAPTMEN1KMT2ATEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 CN claimed
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 US disclosed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 EP disclosed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 WO disclosed
CN-105612150-B Sulfonylindole derivatives and process for producing the same 株式会社大熊制药 2018-04-10 CN disclosed
CN-104168958-B Diaryl sulfonamides useful for the treatment of inflammation and cancer 坎塞拉有限公司 2017-12-01 CN disclosed
CN-104678028-B The pre-treatment of biological original amine neurotransmitters and detection method and detection kit 中国人民解放军军事医学科学院毒物药物研究所 2017-08-15 CN disclosed
CN-105612150-A Sulfonylindole derivatives and process for producing the same DAE WOONG PHARMA 2016-05-25 CN disclosed
CN-105308053-A Spiroindoline derivatives useful as gonadotropin releasing hormone receptor antagonists Bayer Pharma AG 2016-02-03 CN disclosed
CN-105017098-A Preparation technology of alkyloxybenzsulfamide and its derivatives DALIAN QIKAI MEDICAL TECHNOLOGY CO LTD 2015-11-04 CN disclosed
US-20100048582-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-02-25 US disclosed
CN-101641348-A Imidazolidinone derivatives HOFFMANN LA ROCHE CH 2010-02-03 CN disclosed
WO-2009140309-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed
CN-101501032-A Fused tricyclic sulfonamides as gamma secretase inhibitors ELAN PHARM INC (US) 2009-08-05 CN disclosed
EP-2074110-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-07-01 EP disclosed
US-20090131452-A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-05-21 US disclosed
WO-2009056632-A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-05-07 WO disclosed
CN-101421264-A Is suitable for treating serotonin 5HT6Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG (DE) 2009-04-29 CN disclosed
WO-2007118900-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed
CN-101027286-A Indazolone derivatives as 11 b-HSD 1 inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131452-A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR1D, HTR1B TRPV4 374/4885ALDH1A1 1417/4885MAPT 4475/4885
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP TRPV4 4535/4885ALDH1A1 3076/4885MAPT 2653/4885
US-20100048582-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR HTR6, HTR1A, HTR2C TRPV4 347/4885ALDH1A1 1061/4885MAPT 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.